Market Pathways Scorecard: FDA Trends Edition
A graphic look at Q1 2024 approvals and review status.
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
A graphic look at Q1 2024 approvals and review status.
RebrAIn is providing an AI-enabled service that helps neurosurgeons more precisely localize the target of therapy in the individual’s brain to guide more accurate intervention for Parkinson’s disease, essential tremor, and other neurodegenerative disorders.
The EU adds an extra round to its ongoing “scientific advice” pilot for high-risk devices. Excerpted from Pathways’ Picks April 2: EU Advice Pilot Extends, NTAP Watch, FDA Standards Scheme Starts Small.